NUTEK OIDO
Redefining precision in Surgical Oncology, on-the-body cancer tissue detection, during operation
StartupNUTEK OIDO is a Rishon LeTsiyon-based startup in the Health Tech & Life Sciences sector, established in 2019. Redefining precision in Surgical Oncology, on-the-body cancer tissue detection, during operation. The company has raised a total of $1.78M across 6 funding rounds, currently at the Pre-Seed stage. NUTEK OIDO was founded by Dov Cohen, Ofer Braun, Prof. MD. Hanoch Kashtan. The company has 1-10 employees. Core technologies: Sensing, Optic, Artificial Intelligence, Image Recognition, Machine Learning, Simulation & Imaging.
With $1.78M in total funding, NUTEK OIDO is a Pre-Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: R&D. The company holds 1 patent.
- StagePre-Seed
- ProductR&D
- ModelB2B
- Employees1-10
- HQRishon LeTsiyon
- DistrictCenter District
- Last Round$308K
Dov CohenCo-founder & CEO
Ofer BraunCo-founder & CTO
Prof. MD. Hanoch KashtanCo-founder , Medical Director
5 articles covered by sources including brutkasten.com,
www.wirtschaftswelt.at,
jmbdavis.com,
nocamels.com,
www.calcalistech.com.
What does NUTEK OIDO do?
NUTEK takes part in the fight against cancer by pioneering precision in Surgical Oncology. NUTEK is addressing the problem of cancer tissues that remain undetected on the patient's body after surgical intervention, which is the main cause of subsequent cancer recurrence, repeated operations, and aggressive treatments. Furthermore, the resulting economic burden on hospitals, healthcare organizations insurance companies is significantly high. NUTEK provides a unique intraoperative solution, the "Rainbow Probe". A high-resolution hyperspectral imaging handheld device, by which surgeons will scan the operation cavity on-the-patient’s-body during surgery. The probe guides the surgeon prior to closing, to the exact location of remaining cancer tissue, which otherwise could remain undetected, for immediate removal. Conceptual video : https://youtu.be/bcrlMbuwTJA Its first application is Breast Cancer, for which the NOAM Rainbow Probe is developed, to be followed with addressing high-precision and minimally invasive, cancer surgical interventions. . NUTEK won first prize at Paul Merage Institute startup competition and received a major non-dilutive grant from the FFG (Austrian Innovation Authority) for a two years project. NUTEK is collaborating with the Medical University of Graz in Austria and with Assuta Ashdod Hospital in Israel, completed pre-clinical experiment on breast cancer, developed MVP (TRL6) and designed critical parts of the end-product. NUTEK is currently fundraising. Join us on our life-saving mission.
How much funding has NUTEK OIDO raised?
NUTEK OIDO has raised $1.78M in total funding across 6 rounds. The company is currently at the Pre-Seed stage.
Who founded NUTEK OIDO?
NUTEK OIDO was founded in 2019 by Dov Cohen (Co-founder & CEO), Ofer Braun (Co-founder & CTO), Prof. MD. Hanoch Kashtan (Co-founder , Medical Director).
What sector is NUTEK OIDO in?
NUTEK OIDO operates in Health Tech & Life Sciences, Medical Devices, Diagnostics Devices, with core technologies in Sensing, Optic, Artificial Intelligence, Image Recognition, Machine Learning, Simulation & Imaging. Target customers: Healthcare & Life Sciences, Life Sciences, Biotechnology, Medical Devices Industry, Medical Equipment, Healthcare, Laboratories, Providers, Insurance Companies.
Where is NUTEK OIDO located?
NUTEK OIDO is based in Rishon LeTsiyon, Israel, Center District. The company also has offices abroad.